Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs)demonstrate ...

—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in ...

Stoke Therapeutics, Inc. , a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. today announced data presentations ...

Stoke Therapeutics (STOK) and Biogen (BIIB) announced data presentations on zorevunersen, an investigational antisense oligonucleotide, as a ...

In this rapidly approaching reality, what tools will we need not just to survive, but to retain our humanity? We turned to ...

New research published in the journal eNeuro examined whether eliminating a protein that is elevated in the brains of those ...

Essential tremor (ET) is a common movement disorder affecting about 2% of the American population, and more than 20% of those ...